Why the study?
The dynamic and evolving nature of less-invasive aortic valve therapies necessitated further refinements of clinical research processes and endpoint definitions.
Key points are not available for this paper at this time.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The establishment of the VARC-3 definition in 2021 enabled consistent reporting of durability outcomes and more meaningful comparisons between TAVI and SAVR.”
VARC-3 adoption should standardize aortic valve trial reporting; extends prior criteria to enable consistent TAVI–SAVR comparisons.
Acknowledging the dynamic and evolving nature of less-invasive aortic valve therapies, further refinements of clinical research processes are required. The adoption of these updated and newly proposed VARC-3 endpoints and definitions will ensure homogenous event reporting, accurate adjudication, and appropriate comparisons of clinical research studies involving devices and new therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Généreux et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: